 |
| 04-Oct-11 | Upgrade |
JMP Securities |
Mkt Perform → Mkt Outperform |
$4 |
|
| 11-Feb-10 | Upgrade |
WBB Securities |
Buy → Strong Buy |
$6 |
|
| 26-Mar-09 | Initiated |
Wedbush Morgan |
Buy |
|
|
| 10-Mar-09 | Initiated |
Wedbush Morgan |
Buy |
$12 |
|
| 28-Apr-08 | Reiterated |
JMP Securities |
Mkt Outperform |
$10 → $12 |
|
| 18-Mar-08 | Upgrade |
JMP Securities |
Mkt Perform → Mkt Outperform |
|
|
| 26-Feb-08 | Reiterated |
RBC Capital Mkts |
Outperform |
$19 → $13 |
|
| 14-Aug-07 | Downgrade |
JMP Securities |
Mkt Outperform → Mkt Perform |
|
|
| 27-Mar-07 | Reiterated |
JMP Securities |
Mkt Outperform |
$15 → $19 |
|
| 26-Mar-07 | Reiterated |
JMP Securities |
Mkt Outperform |
$15 → $19 |
|
| 06-Feb-07 | Reiterated |
JMP Securities |
Mkt Outperform |
$12 → $15 |
|
|
|
| 23-May-13 09:41AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 22-May-13 09:15AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a EDGAR Online |
| 21-May-13 01:04PM | ALEXZA PHARMACEUTICALS INC. Financials EDGAR Online Financials +5.17% |
| 20-May-13 05:01PM | Teva Bets on Reformulating Old Drugs as Investors Say Show Me at Bloomberg |
| 15-May-13 08:29AM | Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What? at Seeking Alpha |
| 05:17AM | Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning at Seeking Alpha |
| 14-May-13 07:50PM | Alexza Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:00PM | Alexza Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:49PM | Alexza Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:05PM | Alexza Reports 2013 First Quarter Financial Results PR Newswire |
| 09:13AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 13-May-13 03:45PM | Teva - Alexza Sign Deal for Adasuve Zacks |
| 02:04PM | Alexza Pharmaceuticals Earnings Preview: Get Ahead of the Analysts at Wall St. Cheat Sheet |
| 09-May-13 04:45PM | Adasuve Deal Is Very Good For Alexza, But What About Teva? at Investopedia -8.10% |
| 01:21PM | Nasdaq stocks posting largest percentage increases AP |
| 01:04PM | Alexza Pharmaceuticals: Heres What Investors Need to Know Before Earnings at Wall St. Cheat Sheet |
| 07:07AM | Q1 2013 Alexza Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN |
| 08-May-13 09:37PM | 3 Healthcare Stock Stories Prescribed For Investors at Wall St. Cheat Sheet +22.07% |
| 06:03PM | Nasdaq stocks posting largest percentage increases AP |
| 01:30PM | Alexza Pharma jumps on Adasuve licensing deal AP |
| 01:28PM | Nasdaq stocks posting largest percentage increases AP |
| 10:38AM | Teva Sees NTE Sales at $2 Billion in Five Years, R&D Chief Says at Bloomberg |
| 10:04AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi EDGAR Online |
| 09:18AM | Teva to market Alexza agitation treatment in the U.S. at Reuters |
| 09:00AM | Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE scheduled for 9:00 am ET today CCBN |
| 08:35AM | Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S. PR Newswire |
| 08:34AM | InPlay: Alexza Pharma and Teva Pharma (TEVA) announce Teva's license to market ADASUVE in the U.S.; Alexza will receive upfront cash payment of $40 mln (shares halted) Briefing.com |
| 08:30AM | Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S. PR Newswire |
| 08:30AM | Teva and Alexza Announce Tevas License to Market ADASUVE® in the U.S. Business Wire |
| 06-May-13 09:00AM | Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy PR Newswire |
| 02-May-13 11:22AM | Global Opportunity for Generic Drug Players: Central and Eastern Europe, Latin America and Parts of Asia are Areas with Fertile Ground for Continued Growth Wall Street Transcript |
| 01-May-13 07:00PM | Update: Alexza to Report 2013 First Quarter Financial Results on Tuesday, May 14, 2013 PR Newswire |
| 22-Apr-13 05:00PM | Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013 PR Newswire |
| 18-Apr-13 09:15AM | XenoPort: A High Probablity Run-Up Trade at Seeking Alpha |
| 11-Apr-13 10:28AM | 3 Biotechs With Upcoming Product Launches at Seeking Alpha +5.30% |
| 05-Apr-13 10:00AM | On The Fly: Analyst Upgrade Summary theflyonthewall.com |
| 03-Apr-13 10:00AM | On The Fly: Analyst Upgrade Summary theflyonthewall.com |
| 09:25AM | Stock Upgrades: Chipotle Mexican Grill Stock Set to Head North at Minyanville |
| 09:13AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K/A, Change in Directors or Principal Officers EDGAR Online |
| 02-Apr-13 10:10AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online |
| 30-Mar-13 01:04PM | ALEXZA PHARMACEUTICALS INC. Financials EDGAR Online Financials |
| 26-Mar-13 08:50PM | Alexza Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 05:00PM | Alexza Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:05PM | Alexza Reports 2012 Fourth Quarter and Full Year Financial Results PR Newswire |
| 09:12AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 07:34AM | Alexza Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 07:07AM | Q4 2012 Alexza Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN |
| 24-Mar-13 04:30AM | Solving The R&D Investment Dilemma With Project Funding: Mark Kessel at Seeking Alpha |
| 13-Mar-13 04:21PM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online |
| 09:00AM | Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer PR Newswire |
| 06-Mar-13 05:00PM | Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013 PR Newswire |
| 09:17AM | Why Alexza Pharmaceuticals Ran 10% In 5 Minutes at Seeking Alpha |
| 28-Feb-13 11:30AM | U.S. Stock Options With Biggest Changes in Implied Volatility at Bloomberg |
| 25-Feb-13 09:15AM | Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences PR Newswire |
| 21-Feb-13 09:09AM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 09:05AM | InPlay: Alexza Pharma receives marketing authorization for ADASUVE in the EU Briefing.com |
| 09:00AM | Alexza Receives Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European Union PR Newswire |
| 15-Feb-13 11:30AM | U.S. Stock Options With Biggest Changes in Implied Volatility at Bloomberg |
| 14-Feb-13 08:20AM | Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success Marketwire +5.77% |
| 08-Feb-13 04:12PM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 03-Feb-13 03:55AM | MAP's Levadex Ready For FDA Approval at Seeking Alpha |
| 28-Jan-13 03:45AM | Bearish play in Alexza Pharmaceuticals optionMONSTER |
| 25-Jan-13 09:14PM | MAP Investors: X Marks the Buyout at Motley Fool |
| 22-Jan-13 08:20AM | Mergers and Acquisitions on the Rise in 2013 as Big Pharma Companies Hold Record Amounts of Cash on Hand Marketwire |
| 15-Jan-13 01:50PM | This Diagnostic Company May Double in 2013 at Motley Fool |
| 14-Jan-13 05:19PM | Fluidigm Corp. adds Thoratec boss Burbach to board at bizjournals.com |
| 10-Jan-13 11:08AM | FDA Decision On MAP's Levadex Approaching, Stock Starting To Reflect Optimism at Seeking Alpha |
| 08-Jan-13 11:04AM | Bull raises dosage in Alexza Pharma optionMONSTER |
| 03-Jan-13 04:07PM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online |
| 09:00AM | Alexza Pharmaceuticals Appoints J. Kevin Buchi to its Board of Directors PR Newswire |
| 30-Dec-12 07:01AM | 5 of Last Week's Biggest Losers at Motley Fool |
| 26-Dec-12 09:29AM | On The Fly: Pre-market Movers theflyonthewall.com |
| 24-Dec-12 01:44PM | Mondays biggest gaining and declining stocks at MarketWatch -13.82% |
| 12:42PM | Stocks to watch Monday: RIM, Nike, Alexza at MarketWatch |
| 12:14PM | Mondays biggest gaining and declining stocks at MarketWatch |
| 10:58AM | Merry Drugmas! 4 FDA Approvals in 1 Day at Motley Fool |
| 10:12AM | Mondays biggest gaining and declining stocks at MarketWatch |
| 09:15AM | On The Fly: Pre-market Movers theflyonthewall.com |
| 08:44AM | Alexza falls despite FDA approval optionMONSTER |
| 08:44AM | Alexza declines despite FDA approval optionMONSTER |
| 08:09AM | Mondays biggest gaining and declining stocks at MarketWatch |
| 08:00AM | FDA dance card crammed with Bay Area-developed drugs at bizjournals.com |
| 06:54AM | U.S. stock futures sink on fiscal-cliff fears at MarketWatch |
| 06:10AM | Stock futures sink on fiscal-cliff fears at MarketWatch |
| 05:48AM | Stocks to Watch: Regions, Google, RIM TheStreet |
| 05:42AM | Drug Approvals Are Priced In, Wait For The Buying Opportunity at Seeking Alpha |
| 23-Dec-12 08:01AM | Stocks to watch Monday: RIM, Nike, Alexza at MarketWatch |
| 22-Dec-12 12:03PM | This Week in Biotech at Motley Fool |
| 21-Dec-12 06:11PM | Humana Completes Metropolitan Purchase, NPS Sees Gattex Approved: Healthcare Business Report at Wall St. Cheat Sheet -6.91% |
| 05:46PM | UPDATE 1-Alexza's agitation drug gets FDA approval at Reuters |
| 05:42PM | RIM shares extend losses in after-hours trading at MarketWatch |
| 04:21PM | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04:04PM | Alexza Wins U.S. Approval for Inhaled Antipsychotic Drug at Bloomberg |
| 04:00PM | Alexza's agitation drug gets FDA approval at Reuters |
| 03:39PM | Biotech Maestro Alex Zaffaroni's Last Hurrah at Forbes |
| 03:28PM | InPlay: Alexza Pharma: FDA approves ADASUVE inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar 1 disorder in adults (stock halted) Briefing.com |
| 03:25PM | U.S. FDA Approves Alexza's ADASUVE® (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults PR Newswire |
| 01:19PM | Nasdaq stocks posting largest percentage increases AP |
| 20-Dec-12 06:03PM | Nasdaq stocks posting largest percentage increases AP +13.30% |
| 03:00PM | U.S. Stock Options With Biggest Changes in Implied Volatility at Bloomberg |
|
|
| Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company's lead program includes ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Its product candidates include AZ-002 (Staccato alprazolam) for the treatment of acute repetitive seizures. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| LANSDOWNE PARTNERS AUSTRIA GMB | 10% Owner | Jan 18 | Sale | 4.75 | 25,000 | 118,750 | 1,520,055 | Jan 22 12:20 PM | | LANSDOWNE PARTNERS AUSTRIA GMB | 10% Owner | Jan 17 | Sale | 4.75 | 100,000 | 475,000 | 1,545,055 | Jan 22 12:20 PM | | LANSDOWNE PARTNERS AUSTRIA GMB | 10% Owner | Dec 27 | Buy | 4.85 | 72,189 | 350,267 | 1,645,055 | Dec 31 01:56 PM | | Simms Michael J | SVP, Operations & Manuf | Dec 26 | Sale | 4.90 | 4,558 | 22,316 | 4,180 | Dec 27 04:27 PM | | Cassella James V | EVP, R&D and CSO | Dec 26 | Sale | 4.90 | 4,558 | 22,316 | 950 | Dec 27 04:19 PM | | Cassella James V | EVP, R&D and CSO | Aug 27 | Sale | 4.14 | 10,000 | 41,364 | 5,508 | Aug 29 05:39 PM | | KING THOMAS BRAXTON | Pres & CEO | Aug 27 | Sale | 4.14 | 10,000 | 41,364 | 10,229 | Aug 29 05:35 PM | | Moreland Darl | SVP, Quality | Aug 27 | Sale | 4.14 | 10,000 | 41,364 | 1,908 | Aug 29 05:30 PM | | Simms Michael J | SVP, Operations & Manuf | Aug 27 | Sale | 4.14 | 10,000 | 41,364 | 7,957 | Aug 29 05:27 PM | | Oki Mark K | SVP, CFO and Sec | Aug 27 | Sale | 4.14 | 10,000 | 41,364 | 3,788 | Aug 29 05:25 PM | | KING THOMAS BRAXTON | Pres & CEO | Jun 06 | Sale | 0.34 | 65,516 | 22,151 | 202,325 | Jun 08 04:57 PM | | Cassella James V | SVP, Research & Development | Jun 06 | Sale | 0.34 | 46,222 | 15,628 | 157,801 | Jun 08 04:56 PM | | Oki Mark K | VP Fin Controller PAO PFO Sec | Jun 06 | Sale | 0.34 | 31,873 | 10,776 | 137,896 | Jun 08 04:51 PM | | Simms Michael J | SVP, Operations & Manuf | Jun 06 | Sale | 0.34 | 46,222 | 15,628 | 179,603 | Jun 08 04:46 PM |
|
|
|
|
|
|
